
    
      This is a prospective, observational evaluation of immunoglobulin (Ig) therapy in consenting
      adult and assenting pediatric subjects who receive infusion services from BriovaRx Infusion
      Services, (Formerly AxelaCare Health Solutions, LLC). Subjects meeting all inclusion criteria
      who have provided informed consent/assent for trial participation will have validated,
      physician-prescribed, and standard-of-care outcome measures recorded during normal home
      infusion visits. Collected data will be de-identified and aggregated into cohorts of like
      diagnosis for trend analysis.
    
  